The prognostic utility of galectin-3 in patients undergoing cardiac surgery: a scoping review.

Autor:	Shah A; School of Medicine, Queen's University, Kingston, ON, Canada., Ding Y; Institute of Biomedical Engineering, Faculty of Applied Science and Engineering, University of Toronto, Toronto, ON, Canada., Walji D; Faculty of Health Sciences, Queen's University, Kingston, ON, Canada., Rabinovich GA; Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina., Pelletier M; Cardiac Surgery Department, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., El-Diasty M; Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.; Cardiac Surgery Department, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Jazyk:	angličtina
Zdroj:	Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals [Biomarkers] 2024 Nov; Vol. 29 (7), pp. 485-493. Date of Electronic Publication: 2024 Oct 18.
DOI:	10.1080/1354750X.2024.2415073
Abstrakt:	Objective: To review the utility of galectin-3 (Gal-3) as a biomarker for postoperative adverse outcomes in patients undergoing cardiac surgery. Method: This review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic database search was conducted in October 2023. Studies that measured pre- and/or postoperative plasma Gal-3 levels in adult patients undergoing cardiac surgery were included. Primary outcomes included postoperative morbidity and mortality. Results: Out of 391 studies screened, eight studies met the inclusion criteria. Two of the three studies showed that preoperative plasma levels of Gal-3 were associated with acute kidney injury (AKI) after cardiac surgery. Two of the three studies reported a significant increase in preoperative Gal-3 levels in patients who developed postoperative atrial fibrillation (POAF). The addition of Gal-3 to the EuroSCORE II model was found to statistically improve the prediction of both AKI and POAF. Three of the five studies suggested that Gal-3 levels can predict postoperative mortality. Finally, one study suggested that lower preoperative Gal-3 levels was associated with a higher likelihood of achieving left ventricular reverse remodeling (LVRR) after surgery. Conclusions: Gal-3 may play a promising role in predicting adverse outcomes in patients undergoing cardiac surgery. The addition of Gal-3 to clinical risk prediction scores may improve their discriminatory power in this group of patients. Future studies are warranted to justify its incorporation into routine clinical practice.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu